Stephen Andrew Ward

Stephen Andrew Ward

Auto-generated profile, based on publicly available information

Stephen Andrew Ward

Centre for Drugs and Diagnostics, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool, UK

Research Focus & Metrics

Academic Career Length

46Years (1981-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2003 in Nature
Verified
Journal Article
Closed access
UEU. Eckstein-Ludwig
U. Eckstein-Ludwig
RWR. J. Webb
R. J. Webb
IGI. D. A. van Goethem
I. D. A. van Goethem
JEJ. M. East
J. M. East
ALA. G. Lee
A. G. Lee
SKS. Krishna
S. Krishna

12 March 2010 in Molecules
Verified
Journal Article
Open access
PDF file
POPaul M. O’neill
Paul M. O’neill
VBVictoria E. Barton
Victoria E. Barton
SWStephen A. Ward
Stephen A. Ward
Despite international efforts to ‘roll back malaria’ the 2008 World Malaria Report revealed the disease still affects approximately 3 billion people in 109 countries; 45 within the WHO African region. The latest report however does provide some ‘cautious optimism’; more than one third of malarious countries have documented greater than 50% reductions in malaria cases in 2008 compared to 2000. The goal of the Member States at the World Health Assembly and ‘Roll Back Malaria’ (RBM) partnership is to reduce the numbers of malaria cases and deaths recorded in 2000 by 50% or more by the end of 2010. Although malaria is preventable it is most prevalent in poorer countries where prevention is difficult and prophylaxis is generally not an option. The burden of disease has increased by the emergence of multi drug resistant (MDR) parasites which threatens the use of established and cost effective antimalarial agents. After a major change in treatment policies, artemisinins are now the frontline treatment to aid rapid clearance of parasitaemia and quick resolution of symptoms. Since artemisinin and its derivatives are eliminated rapidly, artemisinin combination therapies (ACT’s) are now recommended to delay resistance mechanisms. In spite of these precautionary measures reduced susceptibility of parasites to the artemisinin-based component of ACT’s has developed at the Thai-Cambodian border, a historical ‘hot spot’ for MDR parasite evolution and emergence. This development raises serious concerns for the future of the artemsinins and this is not helped by controversy related to the mode of action. Although a number of potential targets have been proposed the actual mechanism of action remains ambiguous. Interestingly, artemisinins have also shown potent and broad anticancer properties in cell lines and animal models and are becoming established as anti-schistosomal agents. In this review we will discuss the recent evidence explaining bioactivation and potential molecular targets in the chemotherapy of malaria and cancer.

8 February 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
Hanafy  Ismail Hanafy Ismail
Hanafy Ismail
VBVictoria Barton
Victoria Barton
MPMatthew Phanchana
Matthew Phanchana
Sitthivut CharoensutthivarakulSitthivut Charoensutthivarakul
Sitthivut Charoensutthivarakul
MWMichael H. L. Wong
Michael H. L. Wong
SWStephen A. Ward
Stephen A. Ward
The artemisinin (ART)-based antimalarials have contributed significantly to reducing global malaria deaths over the past decade, but we still do not know how they kill parasites. To gain greater insight into the potential mechanisms of ART drug action, we developed a suite of ART activity-based protein profiling probes to identify parasite protein drug targets in situ. Probes were designed to retain biological activity and alkylate the molecular target(s) of Plasmodium falciparum 3D7 parasites in situ. Proteins tagged with the ART probe can then be isolated using click chemistry before identification by liquid chromatography–MS/MS. Using these probes, we define an ART proteome that shows alkylated targets in the glycolytic, hemoglobin degradation, antioxidant defense, and protein synthesis pathways, processes essential for parasite survival. This work reveals the pleiotropic nature of the biological functions targeted by this important class of antimalarial drugs. Significance The mechanism of action of the artemisinin (ART) class of antimalarial drugs, the most important antimalarial drug class in use today, remains controversial, despite more than three decades of intensive research. We have developed an unbiased chemical proteomic approach using a suite of ART activity-based protein profiling probes to identify proteins within the malaria parasite that are alkylated by ART, including proteins involved in glycolysis, hemoglobin metabolism, and redox defense. The data point to a pleiotropic mechanism of drug action for this class and offer a strategy for investigating resistance mechanisms to ART-based drugs as well as mechanisms of action of other endoperoxide-based drugs.

1 January 1998 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
POPaul M. O'Neill
Paul M. O'Neill
PBPatrick G. Bray
Patrick G. Bray
SHShaun R. Hawley
Shaun R. Hawley
SWStephen A. Ward
Stephen A. Ward
BPB.Kevin Park
B.Kevin Park

4 January 2013 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
GNGemma L. Nixon
Gemma L. Nixon
DMDarren M. Moss
Darren M. Moss
ASAlison E. Shone
Alison E. Shone
DLDavid G. Lalloo
David G. Lalloo
NFNicholas Fisher
Nicholas Fisher
GBGiancarlo Augusto Biagini
Giancarlo Augusto Biagini
Atovaquone is used as a fixed-dose combination with proguanil (Malarone) for treating children and adults with uncomplicated malaria or as chemoprophylaxis for preventing malaria in travellers. Indeed, in the USA, between 2009 and 2011, Malarone prescriptions accounted for 70% of all antimalarial pre-travel prescriptions. In 2013 the patent for Malarone will expire, potentially resulting in a wave of low-cost generics. Furthermore, the malaria scientific community has a number of antimalarial quinolones with a related pharmacophore to atovaquone at various stages of pre-clinical development. With this in mind, it is timely here to review the current knowledge of atovaquone, with the purpose of aiding the decision making of clinicians and drug developers involved in the future use of atovaquone generics or atovaquone derivatives.

1 May 2003 in Trends in Parasitology
Verified
Journal Article
Closed access
PBPatrick G. Bray
Patrick G. Bray
MBMichael P. Barrett
Michael P. Barrett
SWStephen A. Ward
Stephen A. Ward
HKHarry De Koning
Harry De Koning